Wedbush Forecasts Strong Price Appreciation for Stoke Therapeutics (NASDAQ:STOK) Stock

Stoke Therapeutics (NASDAQ:STOK) had its price target lifted by investment analysts at Wedbush from $16.00 to $22.00 in a research report issued on Wednesday,Benzinga reports. The firm presently has an “outperform” rating on the stock. Wedbush’s target price would indicate a potential upside of 28.13% from the company’s current price.

STOK has been the subject of a number of other reports. Jefferies Financial Group began coverage on Stoke Therapeutics in a research report on Friday, July 18th. They set a “buy” rating and a $30.00 target price for the company. Needham & Company LLC restated a “buy” rating and issued a $22.00 price target on shares of Stoke Therapeutics in a research report on Tuesday, July 1st. Cantor Fitzgerald upgraded Stoke Therapeutics to a “strong-buy” rating in a research report on Wednesday, May 14th. Finally, HC Wainwright lowered their price target on Stoke Therapeutics from $47.00 to $35.00 and set a “buy” rating for the company in a research report on Wednesday, May 14th. Six investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $25.17.

Stoke Therapeutics Stock Performance

NASDAQ STOK opened at $17.17 on Wednesday. The company has a market capitalization of $940.92 million, a P/E ratio of 20.20 and a beta of 1.15. Stoke Therapeutics has a one year low of $5.35 and a one year high of $17.61. The stock has a 50 day moving average price of $12.41 and a 200-day moving average price of $10.11.

Stoke Therapeutics (NASDAQ:STOK) last posted its earnings results on Tuesday, August 12th. The company reported ($0.40) EPS for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.17. The firm had revenue of $13.82 million during the quarter, compared to the consensus estimate of $31.51 million. Stoke Therapeutics had a return on equity of 18.32% and a net margin of 26.25%. As a group, equities analysts predict that Stoke Therapeutics will post -2.01 EPS for the current fiscal year.

Insiders Place Their Bets

In other Stoke Therapeutics news, insider Barry Ticho sold 4,504 shares of the stock in a transaction on Friday, August 1st. The stock was sold at an average price of $12.82, for a total value of $57,741.28. Following the sale, the insider owned 16,775 shares in the company, valued at $215,055.50. This trade represents a 21.17% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders sold a total of 12,720 shares of company stock valued at $140,095 in the last 90 days. Company insiders own 9.50% of the company’s stock.

Institutional Trading of Stoke Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. GAMMA Investing LLC increased its stake in Stoke Therapeutics by 1,842.0% in the first quarter. GAMMA Investing LLC now owns 5,360 shares of the company’s stock worth $36,000 after purchasing an additional 5,084 shares during the period. Police & Firemen s Retirement System of New Jersey increased its stake in Stoke Therapeutics by 33.2% in the second quarter. Police & Firemen s Retirement System of New Jersey now owns 9,558 shares of the company’s stock worth $108,000 after purchasing an additional 2,384 shares during the period. AlphaQuest LLC purchased a new stake in Stoke Therapeutics in the first quarter worth $72,000. US Bancorp DE increased its stake in Stoke Therapeutics by 9,743.9% in the first quarter. US Bancorp DE now owns 11,222 shares of the company’s stock worth $75,000 after purchasing an additional 11,108 shares during the period. Finally, Tower Research Capital LLC TRC increased its stake in Stoke Therapeutics by 70.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 11,930 shares of the company’s stock worth $132,000 after purchasing an additional 4,918 shares during the period.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.